Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JVRS-100 + Fluzone
- Development stage
- Unknown
- Lead developer
- Colby Pharmaceutical
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
JVRS-100 is a vaccine adjuvant composed of a Cationic Lipid-DNA Complex (CLDC), which includes DOTIM/cholesterol cationic liposomes and non-coding plasmid DNA. Developed by Colby Pharmaceutical Company and licensed from Juvaris BioTherapeutics, JVRS-100 is designed to be administered in combination with vaccines like Sanofi Pasteur's Fluzone (a trivalent inactivated influenza vaccine) to enhance both humoral and cell-mediated immune responses. It acts as a potent immunostimulant, particularly effective in activating CD4+ and CD8+ T-cell responses, making it a candidate for improving vaccine efficacy in elderly populations (65 years and older) who often experience immunosenescence. The drug has been evaluated in Phase I and Phase II clinical trials for seasonal influenza.
- Other names
- CLDCCationic Lipid-DNA Complex
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on JVRS-100 + Fluzone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JVRS-100 + Fluzone.